TPWA
PTGX icon

Twin Peaks Wealth Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.2K Buy
+173
New +$15.3K ﹤0.01% 757
2025
Q3 		– Sell
-171
Closed -$9.32K – 1612
2025
Q2 		$9.32K Buy
+171
New +$8.21K ﹤0.01% 975

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Twin Peaks Wealth Advisors's PTGX Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Protagonist Therapeutics (PTGX) in Q1 2026: 173 shares worth $18.2K. The stake represents ﹤0.01% of the portfolio and ranks #757 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in PTGX as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in PTGX in Q2 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Twin Peaks Wealth Advisors held 173 shares of Protagonist Therapeutics worth $18.2K as of Q1 2026.
  • Protagonist Therapeutics was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #757 holding.
  • Twin Peaks Wealth Advisors first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.